Last September of 2019, Foldax, Inc. announced its first-in-human use of the Tria heart valve under its FDA Early Feasibility Study (EFS) for the treatment of aortic valve disease.Tria heart valves combine LifePolymer™, an advanced biopolymer material, and a patented design to create a valve with the potential lowering the cost of medical care given the increasing costs of using animal tissue valves and the associated durability and calcification concerns. The proprietary biopolymer material and design of the Tria heart valves also allows for high volume manufacturing. The valves are robotically manufactured to provide the highest level of quality and precision and allow for future patient customization, while eliminating the variability of human production.
In this episode of DeviceAlliance’s Medtech Radio, we speak with the Executive Chairman of Foldax Inc., and Exec Chairman Chief Strategy Officer of Compellon Inc. Ken Charhut. Join us as we discuss how this ground breaking technology was created, what major milestone this represents for heart valve patients worldwide, and how the progress toward mitral and transcatheter versions of the valves next year have the potential to revolutionize the heart valve industry.
